Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

323
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
323
Dementia01:30

Dementia

70
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
70
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Genetic Lingo01:11

Genetic Lingo

98.4K
Overview
98.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

319
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
319
Pedigree Analysis01:35

Pedigree Analysis

82.3K
Overview
82.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Soluble Ubiquilin2 in Amyotrophic Lateral Sclerosis Carrying Ubiquilin2 (P494L) Mutation: Clinicopathological and Biochemical Evidence From an Autopsy Case.

Neuropathology and applied neurobiology·2026
Same author

A reappraisal of APOE genetic effects on Alzheimer's disease risk in the Japanese population: a meta-analysis.

Molecular neurodegeneration·2026
Same author

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

CCN1/Cyr61 associates with β-amyloid levels in human cerebrospinal fluids.

iScience·2026
Same author

[Survey on the involvement of Japanese neurologists in genetic medicine].

Rinsho shinkeigaku = Clinical neurology·2026
Same author

Post-mortem diagnosis of CACT deficiency with a novel SLC25A20 variant.

Human genome variation·2026

Related Experiment Video

Updated: May 13, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K

[An Update on Hereditary Dementias].

Takeshi Ikeuchi1

  • 1Department of Molecular Genetics, Brain Research Institute, Niigata University.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 12, 2025
PubMed
Summary
This summary is machine-generated.

Diagnosing hereditary dementias is complex, but genetic testing offers definitive answers. Research is exploring early biomarkers and treatments like gene therapy for these inherited neurodegenerative diseases.

More Related Videos

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.4K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

1.3K

Related Experiment Videos

Last Updated: May 13, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.4K
Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights
07:55

Author Spotlight: Unveiling Mitochondrial Contact Sites and Architectural Insights

Published on: June 16, 2023

1.3K

Area of Science:

  • Neuroscience
  • Genetics
  • Neurology

Background:

  • Mendelian inheritance patterns are linked to specific dementia subtypes.
  • Clinical diagnosis of hereditary dementia is difficult due to overlapping symptoms and varied presentations.
  • Genetic testing is crucial for a definitive diagnosis of hereditary dementia.

Purpose of the Study:

  • To highlight diagnostic challenges in hereditary dementia.
  • To discuss the role of genetic testing and biomarkers.
  • To review current therapeutic strategies and clinical trials for hereditary dementias.

Main Methods:

  • Identification of causative genes for Mendelian dementia subtypes.
  • Analysis of clinical presentations and diagnostic overlaps.
  • Review of biomarker studies in dominantly inherited Alzheimer's disease and hereditary frontotemporal dementia.
  • Examination of ongoing clinical trials for disease-modifying therapies.

Main Results:

  • Pathogenic variants in specific genes confirm hereditary dementia diagnoses.
  • Pre-symptomatic biomarker changes are observed in certain inherited dementias.
  • Clinical trials are evaluating novel treatments, including antibody therapies and gene therapy.

Conclusions:

  • Despite diagnostic complexities, genetic testing provides definitive identification of hereditary dementias.
  • Early detection through biomarkers is advancing research.
  • Therapeutic interventions, including gene therapy, show promise for treating these conditions.